Charles River Laboratories International (NYSE:CRL) Trading 11.3% Higher – Should You Buy?

Charles River Laboratories International, Inc. (NYSE:CRL)’s stock price was up 11.3% during trading on Thursday . The company traded as high as $183.66 and last traded at $183.0280. Approximately 675,337 shares were traded during trading, a decline of 28% from the average daily volume of 942,033 shares. The stock had previously closed at $164.49.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CRL shares. TD Cowen reduced their price objective on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Royal Bank Of Canada began coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target on the stock. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. UBS Group raised their price target on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Finally, JPMorgan Chase & Co. cut their target price on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Monday, April 13th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and an average price target of $207.69.

Charles River Laboratories International Trading Up 10.3%

The firm’s 50-day moving average is $168.04 and its 200 day moving average is $181.10. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The firm has a market capitalization of $8.74 billion, a price-to-earnings ratio of -48.25, a P/E/G ratio of 1.79 and a beta of 1.44.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. During the same period last year, the company earned $2.34 EPS. The firm’s revenue was up 1.2% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CRL. Tema Etfs LLC bought a new position in Charles River Laboratories International during the 4th quarter worth approximately $26,000. Rothschild Investment LLC raised its holdings in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in Charles River Laboratories International during the 3rd quarter worth approximately $31,000. Los Angeles Capital Management LLC bought a new position in Charles River Laboratories International during the 4th quarter worth approximately $42,000. Finally, Sfam LLC bought a new position in Charles River Laboratories International during the 4th quarter worth approximately $43,000. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.